Sequencing and Analysis of John Cunningham Polyomavirus DNA from Acquired Immunodeficiency Syndrome Patients with Progressive Multifocal Leukoencephalopathy
Cai-Qin Hu,Jun-Wei Su,Meng-Yan Wang,Yong-Zheng Guo,Li-Jun Xu,Ran Tao,Yi-Rui Xie,Ying Huang,Biao Zhu
DOI: https://doi.org/10.1097/cm9.0000000000001225
IF: 6.133
2020-01-01
Chinese Medical Journal
Abstract:The John Cunningham (JC) polyomavirus was first discovered in a patient with progressive multifocal leukoencephalopathy (PML) in 1971. The diagnosis for PML includes definite (etiological) diagnosis and presumptive (clinical) diagnosis. The etiological diagnosis consists of cerebrospinal fluid (CSF)-confirmed PML (evidence of JC polyomavirus in the CSF) and tissue-confirmed PML (evidence of JC polyomavirus in brain tissues). The clinical diagnosis of PML is defined as evidence of typical clinical and magnetic resonance imaging (MRI) findings.[1] JC polyomavirus has a non-enveloped, closed circular double-stranded DNA genome with a full length of 5120 kb. The virus genome is composed of an early coding region, a late coding region, and a non-coding control region (NCCR). The early coding region encodes five proteins: the large tumor (T) antigen, the small T antigen, and three other T antigen-splicing variants (T’135, T’136, and T’165). The early coding region regulates viral DNA replication and early gene transcription. The late coding region encodes the proteins VP1, VP2, VP3, and agnoprotein. VP1 protein is the major structural protein and expresses 70% of the viral genes; it plays an important role in the process of virus binding to receptors and entering cells. The NCCR region is a highly variable region in the JC polyomavirus and can be further divided into six blocks: A (nt12–nt36), B (nt37–nt59), C (nt60–nt114), D (nt115–nt180), E (nt181–nt198), and F (nt199–nt267). There are two main forms of NCCR: archetype and rearranged type. The archetype is typified by the CY strain, found in kidney, urine, and lymphoid tissues, seldom in the brain. The rearranged type, also known as PML type, involves deletions, duplications, and rearrangement of specific sequence elements. The rearranged type presents in the CSF and blood of acquired immunodeficiency syndrome (AIDS) patients with PML.[2] JC polyomavirus remains latent in the human urinary system after the initial infection. When the host becomes immunosuppressed, JC polyomavirus is reactivated and proliferates in the urinary system, resulting in viruria. As the virus continues to replicate and is released into peripheral blood, JC polyomavirus can be detected intermittently. Polyomavirus then escapes from peripheral circulation and spreads to lymphoid tissues (including bone marrow). At this time, the NCCR rearrangement and VP1 AA substitutions of JC polyomavirus may occur. When the JC polyomavirus is transmitted to the brain tissue and infects glial cells, the CSF and brain tissue become positive for JC polyomavirus, often leading to PML.[3] According to previous studies, it is known that variations of JC polyomavirus may be present in the CSF and blood. Previously, we analyzed JC polyomavirus in AIDS patients’ urine but did not find AA substitutions in VP1 region.[4] Therefore, blood samples may be a good choice for analysis when brain tissue and CSF are difficult to obtain in patients with a clinical diagnosis of PML. In order to understand the detection of JC polyomavirus in the CSF and blood from AIDS patients with clinical diagnosis of PML, the viral load and sequence variations of JC polyomavirus were analyzed in different types of specimens. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board at the First Affiliated Hospital of Zhejiang University School of Medicine (No. 2018-759). Informed consent was obtained from each participant before data collection. Six patients diagnosed with AIDS and also clinically diagnosed with PML were recruited, clinical and laboratory data were obtained from electronic databases, and MRIs were reviewed by a neuroradiologist. A total of 17 samples were collected, including five CSF samples (patient number 9 had no CSF specimen), six plasma samples, and six peripheral blood mononuclear cell (PBMC) samples. Real-time polymerase chain reaction (PCR) and sequencing of JC polyomavirus were performed in this study. The nucleotide sequences of the VP1-coding region and the rearrangement in the NCCR were both analyzed. All sequences were aligned and analyzed using BioEdit version 7.0.9 (http://www.bioedit.updatestar.com) and MEGA version 7.0.20 (http://www.megasoftware.net). From the experimental results, we found that JC polyomavirus DNA was detected in four specimens among the five clinically diagnosed PML patients with available CSF specimens. The positive rate of JC polyomavirus in CSF was the highest (4/5), followed by plasma samples (2/6), and PBMC samples (1/6). The plasma and PBMC specimens of patient number 9 showed a positive detection for JC polyomavirus DNA, and the viral loads were 5.57 × 104 copies/mL and 3.28 × 104 copies/mL, respectively. Patient number 4 also had a positive plasma specimen, and the viral load of JC polyomavirus DNA was 2.91 × 102 copies/mL [Supplementary Table 1, http://links.lww.com/CM9/A385]. Therefore, among the six patients with clinically diagnosed PML, four patients with positive JC polyomavirus DNA in CSF samples could be etiologically diagnosed with PML, but the other two required further testing. We carried out further sequencing analysis of PCR-positive specimens [Supplementary File, http://links.lww.com/CM9/A385]. The seven JC polyomavirus-positive samples, including four CSF samples, one PBMC sample, and two plasma samples, were subjected to sequencing. Four rearrangements of the NCCR (CSF-15, PBMC-9, Plasma-9, and Plasma-4) were obtained. These rearrangements have not been reported before and are; therefore, new variations identified in this study [Figure 1, Supplementary Figure 1, http://links.lww.com/CM9/A385]. In sample CSF-15, the composition of the NCCR recombinant was Ori-A-B-C-d-E-F, with the deletion of a total of 34 nucleotide (nt28–nt61) in block D [Figure 1A]. In sample Plasma-4, the composition of the NCCR recombinant was Ori-A-B-C-D-E-f-F, and a 30 bp duplicated sequence was inserted into the 23rd nucleotide of block F (nt23–nt52) [Figure 1B]. In samples PBMC-9 and Plasma-9, we also detected NCCR rearrangement, and the composition of the NCCR recombinant was Ori-A-B-C-D-E-f-V-f. A 65 bp sequence was inserted into the F region between nucleotides 7 and 59. This abnormal sequence was labeled region V (nt1–nt65) [Figure 1C].Figure 1: NCCR recombination of John Cunningham polyomavirus in blood and CSF samples. (A) In sample CSF-15, the composition of the NCCR recombinant was Ori-A-B-C-d-E-F, with the deletion of a total of 34 nucleotide (nt28–nt61) in block D. (B) In sample Plasma-4, the composition of the NCCR recombinant was Ori-A-B-C-D-E-f-F, and a 30 bp duplicated sequence was inserted into the 23rd nucleotide of block F (nt23-nt52). (C) In samples PBMC-9 and Plasma-9, the composition of the NCCR recombinant was Ori-A-B-C-D-E-f-V-f. A 65 bp sequence was inserted into the F region between nucleotides 7 and 59. This abnormal sequence was labeled region V (nt1–nt65). CSF: Cerebrospinal fluid; NCCR: Non-coding control region; PBMC: Peripheral blood mononuclear cells.The seven JC polyomavirus-positive samples were also subjected to VP1 sequencing, and four nucleic acid sequences (CSF-15, PBMC-9, Plasma-9, and Plasma-4) were obtained. Four nucleotide substitutions were identified, and the corresponding positions on the CY sequence were nt1622, nt1666, nt1843, and nt2253. Translating the four nucleic acid sequences into amino acids, we found that the corresponding AA positions were 55, 69, 128, and 265 [Supplementary Table 1, http://links.lww.com/CM9/A385, Supplementary Figure 2, http://links.lww.com/CM9/A385]. Among the samples, Plasma-4, Plasma-9, PBMC-9, and CSF-15 had AA substitutions. In sample CSF-15, the leucine at AA position 55 was replaced by phenylalanine, recorded as L55F; in sample Plasma-4, glutamate at AA position 69 was replaced by aspartic acid, recorded as E69D; in samples PBMC-9 and Plasma-9, the asparagine at position 265 was replaced by threonine, recorded as N265T. AA substitutions at positions 55, 69, and 265 have been previously reported to be associated with PML pathogenesis.[5] All VP1 mutations and NCCR rearrangements are listed in Supplementary Table 1, http://links.lww.com/CM9/A385. In recent years, sequence variations and rearrangements of JC polyomavirus have been considered to be closely related to PML pathogenesis and tropism. The NCCR contains transcription factor-binding sites, and the rearranged type upregulates virus replication and transcription, resulting in more neurotropic virus. In addition to the JC polyomavirus detected in the CSF, the virus detected in peripheral blood is related to PML. We found NCCR rearrangements in the sequences of Plasma-4, Plasma-9, and PBMC-9, and they were considered to be related to PML pathogenicity. Analyzing the VP1-coding sequences revealed single AA substitutions in the sequences of Plasma-4, Plasma-9/PBMC-9, and CSF-15. These sequence variations corresponded to N265T, E69D, and L55F. It has been reported in PML patients that AA substitutions at 55, 60, 61, 265, 267, 269, and 271 found in blood and CSF samples are associated with pathogenesis. Three-dimensional modeling of JC polyomavirus capsid protein predicts that the frequently mutated AAs (L55, K60, S265, S267, and S269) are located in the sialic acid-binding site; AA substitution will change the affinity and specificity of the virus to the cell receptor and therefore change virus infectivity and pathogenicity.[5] Studies have shown that when the DNA load of JC polyomavirus in the blood is greater than 2.0 log copies/mL, as the load further increases, the prognosis of PML worsens.[1] Ferretti et al[6] suggested that the presence and level of plasma JC polyomavirus DNA can provide a useful non-invasive biomarker for the diagnosis of PML when JC polyomavirus in the CSF or brain tissue is undetectable. Plasma JC polyomavirus DNA can also be used as a prognostic indicator of PML. Based on the above experimental results and previous research findings, we can conclude that patients number 4 and 9 can be etiologically diagnosed with PML. The small sample size is a limitation in this study. PML is a rare disease, and the incidence has been significantly reduced in the era of anti-viral therapy. Through this article, we have learned that in patients with PML, the presence of JC polyomavirus can be detected not only in CSF but also in blood samples. Moreover, JC polyomavirus does not always appear in its original form: variant forms can also exist in the CSF and blood. The appearance of variants is related to PML pathogenicity and tropism. Therefore, if the CSF and brain tissue are not accessible, a blood sample is also helpful for the etiological diagnosis of PML. Acknowledgements The authors thank all patients who participated in this study. Funding This work was supported by a grant from the National Major Science and Technology Projects for Important Infectious Diseases in China (No. 2017ZX10202102-002-002). Conflicts of interest None.